4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

VGL101 demonstrated favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohortsVGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engagement further validating its mechanism of action On track to initiate Phase 2 trial with a 20 mg/kg dose of VGL101 in ALSP patients this quarterCompany to host conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced interim topline r

4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

SC 13D/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

SC 13G - Vigil Neuroscience, Inc. (0001827087) (Subject)

SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

SC 13G - Vigil Neuroscience, Inc. (0001827087) (Subject)

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will be presenting at the following conferences in November: Stifel 2024 Healthcare ConferenceFormat: Fireside ChatDate/Time: Monday, November 18th at 4:45 p.m. ET Jefferies London Healthcare ConferenceFormat: Fireside ChatDate/Time: Wednesday, November 20th at 8:30 a.m. GMT The webcasts will also be available on the Company's website in the "Investors" section under "Events & Presentations." Archived webcasts will be available for

- Final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP planned for first half of 2025 - - Data from Phase 1 clinical trial evaluating VG-3927 in Alzheimer's Disease on track for first quarter of 2025 - WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2024, and provided an update on recent progress. "Our accomplishments in the third quarter have provided significant momentum as we continue to

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 11, 2024, at 10:30 a.m. ET. To register for the live webcast, please click here. The webcast will also be available on the Company's website in the "Investors" section under "Events & Presentations." An archived webcast will be available for approximately 90 days following the event. . About Vigil Neuroscience Vigil Neuroscience

WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial of VG-3927. The FDA's decision was based on a complete response submitted by the Company. "We are pleased with the resolution of the partial clinical hold – a decision that was supported by non-clinical and clinical data from our ongoing Phase 1 trial," said Petra Kaufmann, M.D., F.A.A.N., Chief Medical Officer at Vigil. "Whil

WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET. To register for the live webcast, please click here. The webcast will also be available on the Company's website in the "Investors" section under "Events & Presentations." An archived webcast will be available for approximately 90 days following the event. About Vigil Neuroscience Vigil Neuroscience is a

WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences. Morgan Stanley 22nd Annual Global Healthcare ConferenceFormat: Fireside ChatDate/Time: Thursday, September 5th at 2:35 p.m. ET H.C. Wainwright 26th Annual Global Investment Conference Format: Fireside ChatDate/Time: Tuesday, September 10th at 10:30 a.m. ET The live webcasts from the events will be available on the Company's website on the "Events & Presentatio

- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathway in ALSP - - Announced interim data from VG-3927 Phase 1 trial in healthy volunteers that support continued development as potential therapy for Alzheimer's disease - WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2024, and provided an updat

- CSF1R pathogenic and likely pathogenic variants reported to have an approximate prevalence of 281 per 1 million - - New research supports updated estimates to U.S. prevalence of approximately 19,000 and approximately 29,000 in the EU and UK - WATERTOWN, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced a peer-reviewed research publication that reported new data on the prevalence and clinical significance of CSF1R gene variants in the UK population. The research, published in the journal Neurology Genetics a

- First presentation of clinical data on sTREM2 from SAD cohorts in ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers demonstrate proof-of-pharmacology - - New in vitro and in vivo data demonstrate the Company's small molecule TREM2 agonists modulate AD pathophysiology - WATERTOWN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented one oral and two poster presentations at the 2024 Alzheimer's Association International Conference (AAIC) being held July 28 - August 1, 2024 in Philadelphia, Pennsylv

- Safety, tolerability, pharmacokinetic and pharmacodynamic profile of VG-3927 supports continued development as potential once-daily oral therapy for Alzheimer's disease (AD) - - VG-3927 achieved robust decrease of sTREM2 in CSF demonstrating clinical proof-of-target engagement- - New preclinical and clinical data from SAD cohorts to be presented at upcoming 2024 Alzheimer's Association International Conference (AAIC) - - Company plans to report complete Phase 1 data, including data from AD cohort, in Q1'2025 -   WATERTOWN, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of micro

Morgan Stanley downgraded Vigil Neuroscience from Equal-Weight to Underweight and set a new price target of $4.00 from $13.00 previously

JMP Securities initiated coverage of Vigil Neuroscience with a rating of Mkt Outperform and set a new price target of $23.00

Mizuho initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $15.00

Wedbush initiated coverage of Vigil Neuroscience with a rating of Outperform and set a new price target of $19.00

H.C. Wainwright initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $24.00

Morgan Stanley initiated coverage of Vigil Neuroscience with a rating of Equal-Weight and set a new price target of $17.00

Guggenheim initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $23.00

Stifel initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $24.00

Jefferies initiated coverage of Vigil Neuroscience with a rating of Buy and set a new price target of $20.00

Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study Gerhard Koenig appointed as executive chairman of Augustine's Board of Directors Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gem

– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer's disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent progress. "During the quarter, we continued to progress iluzanebart, our monoclonal antibody, and VG-3927, our or

– Reported positive interim data from Phase 2 IGNITE proof-of-concept clinical trial evaluating iluzanebart (VGL101) for treatment of ALSP – – Enrollment for IGNITE trial completed with 20 patients enrolled; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer clinical trial evaluating VG-3927 ongoing; Interim data analysis on track for mid-2024 – – Appointed biotech industry executive Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer – WATERTOWN, Mass., March 26, 2024 (GLOBE NEWSWIRE) --  Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseas

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer. Dr. Kaufmann succeeds Christopher J. Silber, M.D. "Dr. Kaufmann brings a wealth of experience that will be invaluable to the Vigil team," said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "As we further the development of both iluzanebart and VG-3927, we will benefit from her extensive background in neurological and rare

- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 - - Small molecule TREM2 agonist IND submission and initiation of Phase 1 clinical trial on track for fourth quarter of 2023 - - Appoints drug development veteran Christopher J. Silber, M.D. as Chief Medical Officer - WATERTOWN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2023, and provided an update on its r

WATERTOWN, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Christopher J. Silber, M.D. as Chief Medical Officer. Dr. Silber brings over 30 years of biopharmaceutical industry experience and a track record of clinical and regulatory success developing novel therapeutics in neuroscience. "We are thrilled to welcome Dr. Silber to Vigil as our new Chief Medical Officer at this pivotal time as we advance VGL101 through Phase 2 clinical development and work towards moving our small molecule prog

WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced it appointed Samantha Budd Haeberlein, Ph.D. to its Board of Directors. "We are pleased to welcome Samantha Budd Haeberlein to our Board of Directors. Samantha is a distinguished leader in the pharmaceutical industry and brings extensive translational medicine, clinical development and global regulatory experience in the CNS space, including rare and common neurological disorders," said Ivana Magovčević-Liebisch Ph.D., J.D., President and Chief Execut

– Dr. David Gray brings nearly 20 years of preclinical and clinical research and drug development expertise in neurological diseases –    – Dr. Spyros Papapetropoulos to depart Vigil to pursue a Chief Executive Officer opportunity – CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that David Gray, Ph.D., will join the Company as Chief Scientific Officer, effective February 27, 2023. Vigil also announced that Spyros Papapetropoulos, M.D., Ph.D., Chief Medical Officer of Vigil, will leave the Compan

– Initiated a Phase 1 trial of VGL101 in healthy volunteers in Australia – – Received U.S. FDA orphan drug designation for VGL101 for the treatment of patients with ALSP – – Prioritizing VGL101 in ALSP and small molecule TREM2 agonist programs; cash runway now extended through the end of the second quarter of 2024 – – On track to report top line data from the VGL101 Phase 1 trial in healthy volunteers and initiate the Phase 2 trial in ALSP patients in the fourth quarter of 2022 – – Further strengthened Board of Directors with appointment of Suzanne Bruhn, Ph.D. – CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Suzanne Bruhn, Ph.D. to its Board of Directors. "We are excited to have such a well-respected industry leader with over 20 years of executive leadership experience in the biopharmaceutical industry join our Board of Directors," said Ivana Magovčević-Liebisch Ph.D., J.D., President and Chief Executive Officer of Vigil. "Sue's deep operational and global regulatory experience as well as her extensive knowledge of the rare disease and